SCHEMBL20596490

SCHEMBL20596490

COc1ccc(-c2cccc3nc(CC(=O)Nc4ccc(Cl)nc4N)cn23)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 4/20 0.42
▸ LMNA P02545 6/20 0.41
▸ JAK1 P23458 2/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CRHR1 P34998 1/20 0.37
▸ MAPT P10636 5/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20596076 0.89 NOD2 (0.38) LMNAMEN1MAPK1KMT2AALDH1A1
SCHEMBL20595835 0.86 MEN1 (0.38) LMNAMEN1MAPK1KMT2AALDH1A1
SCHEMBL23419563 0.83 MARS2 (0.46) MARS2LMNAMEN1MAPK1KMT2A
SCHEMBL20596051 0.83 CA12 (0.37) LMNAMEN1MAPK1KMT2AALDH1A1
SCHEMBL30145335 0.83 MARS2 (0.43) MARS2JAK1MAPK1SMN1; SMN2CRHR1
SCHEMBL30145317 0.82 MARS2 (0.44) MARS2JAK1MAPK1ALDH1A1SMN1; SMN2
SCHEMBL20596534 0.80 LMNA (0.39) LMNAMEN1MAPK1KMT2AALDH1A1
SCHEMBL20596512 0.78 F10 (0.44) MARS2JAK1MEN1MAPK1KMT2A
SCHEMBL20595923 0.77 CYP1A2 (0.39) LMNAMEN1MAPK1KMT2AALDH1A1
SCHEMBL23419199 0.76 MARS2 (0.41) MARS2LMNAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885LMNA 3342/4885JAK1 1522/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885LMNA 2770/4885JAK1 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback